RGEN Repligen: Business Value to Revenue

repligen.com (RGEN) - corporate logo

Repligen Corporation is recognized as the benchmark in biopharmaceutical equipment, having earned the absolute trust of global scientific centers. High-tech plants in Europe and the US ensure the strictest sterile control and supply chain continuity. The business value-to-revenue multiple has reached 13297.72, confirming high profitability driven by stable demand for ancillary consumables.

RGEN - Repligen Enterprise Value-to-Revenue Ratio over the range 11/23/2025 - 11/20/2026

Repligen Corp - analytical breakdowns and key metrics (RGEN)

- price and consensus price forecast:
- company stock capitalization data:
Fundamental valuation:Repligen Corporation (RGEN)
Product sample of Repligen

This indicator determines the business value, including debt and excluding cash, relative to annual sales to identify objective market overvaluation. By analyzing the EV/Sales ratio of Repligen Corporation (RGEN), an investor can assess the monetization efficiency of Repligen Corporation (RGEN) high-tech automated filtration systems, where the asset's high valuation is justified by the replacement of manual labor in biopharmaceuticals with intelligent equipment.

Competitor analysis for Repligen Corporation

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|RNA (Avidity Corp) - EV/Sales Multiple|CRISPR Therapeutics Corp - Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio genedx.com (WGS)|EV/Sales Multiple ultragenyx.com (RARE)|EV/Sales Multiple BEAM (Beam Therapeutics Inc)|Sarepta Therapeutics Inc (SRPT) - Enterprise Value-to-Revenue Multiple|twistbioscience.com - EV/Sales Multiple|10x Genomics, Inc. - Enterprise Value-to-Revenue Coefficient|NTLA (Intellia Corp) - Company Value to Revenue|Company Value to Revenue stoketherapeutics.com|Company Value to Revenue BLFS|Company Value to Revenue Wave Life Sciences Corp (WVE)|EV/Sales Multiple MAZE|Total Company Value-to-Revenue Ratio Sionna Therapeutics Inc|Enterprise Value-to-Revenue Ratio Prime Medicine Corp PRME|tayshagtx.com (TSHA) - Enterprise Value-to-Revenue Multiple|QURE - Enterprise Value-to-Revenue Ratio|MeiraGTx Holdings (MGTX) - Company Value to Revenue|Regenxbio (RGNX) - Enterprise Value-to-Revenue Ratio|SLDB - Total Company Value-to-Revenue Ratio|OCGN (Ocugen Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio PACB|Enterprise Value-to-Revenue Ratio Benitec (BNTC)|Design Therapeutics Inc - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Rocket Pharma RCKT|EV/Sales Multiple 4DMT FDMT|LXEO - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Korro Bio Inc.|EDIT: EV/Sales Multiple|SLN - Total Company Value-to-Revenue Ratio|PRQR (ProQR Therapeutics) - EV/Sales Multiple|codexis.com (CDXS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple SGMO|EV/Sales Multiple Nautilus Biotechnology, Inc. (NAUT)|EV/Sales Multiple MGX (Metagenomi Inc.)|Business Value to Revenue DTIL|Generation Bio Co. - EV/Sales Multiple|BOLD: Enterprise Value-to-Revenue Ratio|XCUR (Exicure, Inc.) - Company Value to Revenue|Company Value to Revenue Ratio IMNN|Enterprise Value-to-Revenue Ratio RXi Pharmaceuticals|mustangbio.com (MBIO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio TransCode (RNAZ)|Bionano Genomics Inc. - Company Value to Revenue Ratio|Applied DNA Sciences - Company Value to Revenue|Total Company Value-to-Revenue Ratio bluebirdbio.com (BLUE)|IPA - Enterprise Value-to-Revenue Ratio|OMGA - EV/Sales Multiple|OMIC (Singular Genomics Systems, Inc.) - Company Value to Revenue|Regulus Therapeutics Inc - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple